These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 18501489

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [Abstract] [Full Text] [Related]

  • 23. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA, Dorato MA.
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
    Pugsley MK.
    J Pharmacol Toxicol Methods; 2005 Aug; 52(1):1-5. PubMed ID: 15982903
    [Abstract] [Full Text] [Related]

  • 26. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA, Sagartz JE, Morris DL.
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [Abstract] [Full Text] [Related]

  • 27. Methods in safety pharmacology in focus.
    Pugsley MK, Gallacher DJ, Towart R, Authier S, Curtis MJ.
    J Pharmacol Toxicol Methods; 2008 Aug; 58(2):69-71. PubMed ID: 18707009
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK, Curtis MJ.
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals.
    Claude JR, Claude N.
    Toxicol Lett; 2004 Jun 15; 151(1):25-8. PubMed ID: 15177637
    [Abstract] [Full Text] [Related]

  • 32. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM, Makarov VA, Novikova NV.
    Farmakol Toksikol; 1982 Jun 15; 45(3):5-12. PubMed ID: 7047211
    [Abstract] [Full Text] [Related]

  • 33. Nonclinical development of biopharmaceuticals.
    Baumann A.
    Drug Discov Today; 2009 Dec 15; 14(23-24):1112-22. PubMed ID: 19853058
    [Abstract] [Full Text] [Related]

  • 34. An integrated, multidisciplinary approach for drug safety assessment.
    Li AP.
    Drug Discov Today; 2004 Aug 15; 9(16):687-93. PubMed ID: 15341779
    [No Abstract] [Full Text] [Related]

  • 35. [Place and role of safety pharmacology in drug development].
    Guillon JM.
    Ann Pharm Fr; 2010 Sep 15; 68(5):291-300. PubMed ID: 20850000
    [Abstract] [Full Text] [Related]

  • 36. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM, Amouzadeh HR, Engwall MJ.
    Expert Opin Drug Saf; 2013 Jan 15; 12(1):91-102. PubMed ID: 23170873
    [Abstract] [Full Text] [Related]

  • 37. Snapshot PK: a rapid rodent in vivo preclinical screening approach.
    Liu B, Chang J, Gordon WP, Isbell J, Zhou Y, Tuntland T.
    Drug Discov Today; 2008 Apr 15; 13(7-8):360-7. PubMed ID: 18405850
    [Abstract] [Full Text] [Related]

  • 38. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies.
    Benbow JW, Aubrecht J, Banker MJ, Nettleton D, Aleo MD.
    Toxicol Lett; 2010 Sep 01; 197(3):175-82. PubMed ID: 20576494
    [Abstract] [Full Text] [Related]

  • 39. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK, Hancox JC, Curtis MJ.
    Pharmacol Ther; 2008 Aug 01; 119(2):115-7. PubMed ID: 18590766
    [Abstract] [Full Text] [Related]

  • 40. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R, Coats S.
    IDrugs; 2009 Feb 01; 12(2):103-8. PubMed ID: 19204884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.